The Australia fertility services market size reached USD 1.29 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 3.68 Billion by 2033, exhibiting a growth rate (CAGR) of 11.03% during 2025-2033. Rising demand driven by delayed parenthood, increased infertility diagnoses, broader awareness, technological advances like genetic screening, and growing adoption of fertility preservation highlight the sector’s momentum. These drivers, combined with expanding accessibility and supportive healthcare initiatives, are some of the factors contributing to Australia fertility services market share.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024 | USD 1.29 Billion |
Market Forecast in 2033 | USD 3.68 Billion |
Market Growth Rate 2025-2033 | 11.03% |
Expanding Access to Reproductive Healthcare
The fertility services market in Australia is seeing growth as affordability and access to reproductive treatments improve. Broader availability of advanced contraceptives, targeted therapies for conditions like endometriosis, and wider use of hormone-based support for IVF are reshaping patient care pathways. These developments reduce cost barriers, encouraging more individuals to pursue family planning and fertility treatments earlier. The market is also benefiting from increased demand for specialized clinics that can deliver comprehensive reproductive care. With supportive healthcare policies and rising awareness of treatment options, providers are expected to see higher patient volumes, stronger adoption of innovative therapies, and a more inclusive approach to reproductive health across the country. These factors are intensifying the Australia fertility services market growth. For example, in March 2025, the Australian Government expanded Pharmaceutical Benefits Scheme listings to make contraception, endometriosis treatments, and IVF medications more accessible. The new listings include Slinda (progestogen-only contraceptive), Ryeqo (endometriosis), and broader access to Pergoveris (IVF hormone therapy).
Public Support for Fertility Care
Fertility services in Queensland are being reshaped through new public funding that improves access for residents affected by serious illnesses such as cancer. The initiative directs resources toward subsidized assisted reproductive technology within public hospitals, reducing financial strain for patients who often face additional medical costs. Alongside clinical support, counselling services are being integrated to address the emotional and psychological challenges linked to treatment. This approach not only broadens access to fertility care but also emphasizes patient well-being through combined medical and emotional support. The policy shift is expected to strengthen demand for fertility services in the state, foster equitable access across income groups, and set a precedent for integrating reproductive care into broader public health planning. For instance, in March 2024, Queensland’s government unveiled a public funding package to expand fertility treatment access for residents who have faced serious illnesses like cancer. The initiative allocates funds for subsidized assisted reproductive technology in public hospitals and includes counselling services to support those undergoing treatment.
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on cause of infertility, procedure, service, and end user.
Cause of Infertility Insights:
The report has provided a detailed breakup and analysis of the market based on the cause of infertility. This includes male infertility and female infertility.
Procedure Insights:
The report has provided a detailed breakup and analysis of the market based on the procedure. This includes in vitro fertilization with intracytoplasmic sperm injection (IVF with ICSI), surrogacy, in vitro fertilization without intracytoplasmic sperm injection (IVF without ICSI), intrauterine insemination (IUI), and others.
Service Insights:
The report has provided a detailed breakup and analysis of the market based on the service. This includes fresh non-donor, frozen non-donor, egg and embryo banking, fresh donor, and frozen donor.
End User Insights:
A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes fertility clinics, hospitals, surgical centers, clinical research institutes, and cryobanks.
Regional Insights:
The report has also provided a comprehensive analysis of all the major regional markets, which include Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, and Western Australia.
The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Scope of the Report |
Exploration of Historical Trends and Market Outlook, Industry Catalysts and Challenges, Segment-Wise Historical and Future Market Assessment:
|
Cause of Infertilities Covered | Male Infertility, Female Infertility |
Procedures Covered | In Vitro Fertilization with Intracytoplasmic Sperm Injection (IVF with ICSI), Surrogacy, In Vitro Fertilization Without Intracytoplasmic Sperm Injection (IVF without ICSI), Intrauterine Insemination (IUI), Others |
Services Covered | Fresh Non-Donor, Frozen Non-Donor, Egg and Embryo Banking, Fresh Donor, Frozen Donor |
End Users Covered | Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes, Cryobanks |
Regions Covered | Australia Capital Territory & New South Wales, Victoria & Tasmania, Queensland, Northern Territory & Southern Australia, Western Australia |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
Key Benefits for Stakeholders: